Well diffusion for antifungal susceptibility testing

International Journal of Infectious Diseases

Volumn 8, Issue 1, 2004, Pages 39-45

  Magaldi, S ^a   Mata Essayag, Sofia ^a,c   Hartung De Capriles, C ^a   Perez, C ^a   Colella, M T ^a   Olaizola, Carolina ^a   Ontiveros, Yudith ^b  

^a UNIVERSIDAD CENTRAL DE VENEZUELA   (Venezuela)

^b UNIVERSIDAD CENTROCCIDENTAL LISANDRO ALVARADO   (Venezuela)

^c NONE   (Venezuela)

Author keywords

Candida sp.; NCCLS; Susceptibility testing; Well diffusion

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; CASPOFUNGIN; FLUCONAZOLE; ITRACONAZOLE; POSACONAZOLE;

ANALYTIC METHOD; ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA; DIFFUSION; DRUG SENSITIVITY; FUNGUS ISOLATION; GENETIC SUSCEPTIBILITY; LABORATORY TEST; MINIMUM INHIBITORY CONCENTRATION; MYCOSIS; REPRODUCIBILITY; SPECIES DIFFERENTIATION; STANDARDIZATION; WILCOXON SIGNED RANKS TEST;

EID: 0347717954     PISSN: 12019712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijid.2003.03.002     Document Type: Article

References (23)

1. Arias A, Arévalo MP, Andrew A, et al. In vitro susceptibility of 545 isolates of Candida spp. to four antifungal agents. Mycoses 1994;37:285.
2. Dannaoui E, Lacoste V, Prat C, et al. Fluconazole susceptibility of Candida isolates from oropharyngeal candidosis. Mycoses 1997;40:279-82.
3. Espinel-Ingroff A, Barchiesi F, Hazen K, et al. Standardization of antifungal susceptibility testing and clinical relevance. Medical Mycology 1998;36:68-78.
4. Espinel-Ingroff A, Warnock DW, et al. 'In vitro' antifungal susceptibility methods and clinical implications of antifungal resistance. Medical Mycology 2000;38:293-304.
5. Fegeler W, Bille J, Dupont B, et al. Distribution of yeast species in clinical routine diagnostic specimen and their susceptibility against fluconazole, voriconazole and flucytosine. Mycoses 1999;42:174.
6. Klepser M.E. Antifungal resistance among Candida species. Pharmacotherapy 2001;21(8):124-2.
7. Law D, Moore CB, Joseph LA, et al. High incidence of antifungal drug resistance in Candida tropicalis. Int J Antimicrob Agents 1996;7:241-5.
8. Coleman DC, Rinaldi MG, Haynes KA, Rex JH, Summerbell RC, Anaissie EJ. Importance of Candida species other than Candida albicans as opportunistic pathogens. Med Mycol 1998;36(suppl 1):156-65.
9. Redding S, Smith J, Farinacci G, et al. Resistance of Candida albicans to fluconazole during treatment of oropharyngeal candidiasis in a patient with AIDS: documentation by in vitro susceptibility testing and DNA subtype analysis. Clin Infect Dis 1994;18:240-2.
10. Ruhnke M, Egler A, Tennagen I, et al. Emergence of fluconazole-resistant strains of Candida albicans in patients with recurrent oropharyngeal candidosis and human immunodeficiency virus infection. J Clin Microbiol 1994;32:2092-8.
11. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeast. Approved standard M27-A. PA: National Committee for Clinical Laboratory Standards Wayne. 1997.
12. Magaldi S, Camero T. Susceptibilidad de Candida albicans 'in vitro' mediante los pozos de difusión. Boletín Venezolano de Infectologia 1997;7:5-8.
13. Magaldi S, Camero T, Mata S, et al. Pruebas de sensibilidad de Candida albicans frente a los antimicóticos de uso comercial. Boletín Sociedad Venezolana de Microbiología 1998;18:16-20.
14. Magaldi S, Mata S, Camero T, et al. Determinación de la sensibilidad antifúngica en agentes de cromomicosis mediante la técnica de los pozos de difusión. Antibióticos e Infección 1999;7:17-20.
15. Magaldi S, Mata S, Hartung C, et al. 'In vitro' susceptibility of 137 Candida sp. isolates from HIV positive patients to several antifungal drugs. Mycopathologia 2000;149:63-8.
16. Magaldi S, Mata S, Hartung C, et al. In vitro susceptibility to fluconazole of Candida spp. isolates comparing three different methods. J Mycol Med 2001;11:123-6.
17. Feo M. The 'nascent culture' and its use. Mycopathologia 1977;63:185-6.
18. Le Guennec R, Mallie M, Bastide JM. Détermination de la sensibilité des levures aux antifongiques par la méthode du E test: comparaison du milieu Casitone et du milieu RPMI 1640. J Mycol Méd 1997;7:117-22.
19. Pfaller M, Rex JH, Rinaldi MG. Antifungal susceptibility testing: technical advances and potential clinical applications. Clin Infect Dis 1997;24:776-8.
20. Pfaller MA, Diekema DJ, Messer SA, et al. In-vitro activities of caspofungin compared with those for fluconazole and itraconazole against 3.959 clinical isolates of Candida spp. including 157 fluconazole-resistant isolates. Abstract: M-1523 Citation: 42nd ICAAC Abstracts. American society for Microbiology. 2002 Sept 27-30 San Diego, CA, p 412.
21. Vazquez JA, Nagappan V, Boikov D In vitro evaluation of caspofungin acetate (Cancidas) against Candida glabrata: MICs, MFCs, time kill and synergy assays. Abstract: M-1509 42 Citation: 42nd ICAAC Abstracts. American Society for Microbiology. 2002 Sept 27-30 San Diego, CA, p 412.
22. Bartizal K, Motyl M, Hicks P, Sable C, Dinubile M, Kartsonis N. In vitro susceptibility results and correlation with outcome: Results from the randomized invasive candidiasis (IC) study of caspofungin (CAS) vs. amphotericin B (AmB). Abstract: M-1240 Citation: 42nd ICAAC Abstracts. American Society for Microbiology. 2002 Sept 27-30; 2002; San Diego, CA, p 412.
23. Rex JH, Pfaller M, Galgiani J, et al. Development of interpretative breakpoints for antifungal susceptibility testing; conceptual framework and analysis of in vitro correlation data for fluconazole and itraconazole and Candida infections. Clin Infect Dis 1997;24:235-47.